Skip to content

Released Aug 5, 2021, after the close

10-Q filed Aug 6, 2021, 37 days after period end · 0001162194-21-000072

Q2 2021 · 10-Q
Revenue$31.02M+19.0% vs Q2 2020−5.4% vs Q1 2021
Net Income-$17.14MN/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.23N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$17,268,000N/M
Operating Cash Flowderived-$14,664,000N/M
Free Cash Flowderived-$18,836,000N/M
Margins · derived
Operating margin-55.7%−3.0 pt vs Q2 2020
Net margin-55.3%−5.3 pt vs Q2 2020

What the release said

The release

Same quarter

MetricQ2 2021Q2 2020Q2 2019Q2 2018
Revenue$31.02M$26.06M$28.20M$26.43M
Net Income-$17.14M-$13.02M-$13.75M-$16.24M
EPS Diluted-$0.23-$0.18-$0.20-$0.42

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR